You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent/refractory childhood Hodgkin lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recruiting
  • Recurrent Childhood Acute Myeloid Leukemia
  • +17 more
    • Miami, Florida
      Nicklaus Children's Hospital
    May 13, 2023

    Ex Vivo Drug Sensitivity Testing and Mutation Profiling

    Completed
    • Recurrent Childhood Acute Myeloid Leukemia
    • +13 more
      • Miami, Florida
        Nicklaus Children's Hospital
      Jan 18, 2023

      Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

      Recruiting
      • Recurrent Acute Lymphoblastic Leukemia
      • +10 more
      • Houston, Texas
        M D Anderson Cancer Center
      Sep 21, 2022

      Advanced Malignant Solid Tumor, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin

      Active, not recruiting
      • Advanced Malignant Solid Neoplasm
      • +35 more
      • Birmingham, Alabama
      • +113 more
      Jun 28, 2022

      Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With

      Active, not recruiting
      • Adult Acute Lymphoblastic Leukemia in Remission
      • +46 more
      • Philadelphia, Pennsylvania
        Thomas Jefferson University
      Feb 10, 2021

      Advanced Malignant Solid Tumor, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

      Active, not recruiting
      • Advanced Malignant Solid Neoplasm
      • +31 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Birmingham, Alabama
      • +118 more
      Jan 27, 2023

      Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,

      Terminated
      Has Results
      • Acute Biphenotypic Leukemia
      • +29 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jan 4, 2023

      Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

      Suspended
      • Recurrent Aggressive Non-Hodgkin Lymphoma
      • +5 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Jan 12, 2023

      Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

      Recruiting
      • Recurrent Anaplastic Large Cell Lymphoma
      • +9 more
      • Anti-CD30/CD16A Monoclonal Antibody AFM13
      • +4 more
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 9, 2022

      Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial in Puerto

      Recruiting
      • Malignant Solid Neoplasm
      • +26 more
      • Birmingham, Alabama
      • +121 more
      Aug 24, 2022

      Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

      Active, not recruiting
      • Recurrent Anaplastic Large Cell Lymphoma
      • +10 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 30, 2023

      Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

      Recruiting
      • Advanced Malignant Solid Neoplasm
      • +32 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Birmingham, Alabama
      • +124 more
      Aug 24, 2022

      Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

      Recruiting
      • Relapsed or Refractory Hodgkin Lymphoma
      • Beijing, Beijing, China
        Han wei dong
      Jun 14, 2023

      Advanced Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial

      Recruiting
      • Advanced Malignant Solid Neoplasm
      • +30 more
      • Larotrectinib Sulfate
      • Birmingham, Alabama
      • +123 more
      Aug 23, 2022

      Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

      Recruiting
      • Grade 3a Follicular Lymphoma
      • +14 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Atlanta, Georgia
      • +1 more
      May 31, 2022

      Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

      Recruiting
      • Recurrent B-Cell Non-Hodgkin Lymphoma
      • +20 more
      • Chimeric Antigen Receptor T-Cell Therapy
      • +4 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jul 11, 2022

      Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

      Not yet recruiting
      • Non-hodgkin's Lymphoma
      • Beijing, Beijing, China
        Beijing Cancer Hospital
      Sep 27, 2023

      Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

      Not yet recruiting
      • Relapsed/Refractory Non-Hodgkin Lymphoma
      • Duarte, California
      • +1 more
      Oct 13, 2023

      Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

      Completed
      • Grade 3a Follicular Lymphoma
      • +9 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 31, 2023

      Recurrent/Refractory Classical Hodgkin's Lymphoma Trial in Tianjin (AK105,Anrotinib HCl)

      Enrolling by invitation
      • Recurrent/Refractory Classical Hodgkin's Lymphoma
      • AK105，Anrotinib hydrochloride
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Insititute & Hospital
      Jan 12, 2023

      Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

      Not yet recruiting
      • Classical Hodgkin Lymphoma
      • Non-Hodgkin Lymphoma
      • GEN3017
      • (no location specified)
      Aug 25, 2023

      Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma Trial in Detroit (filgrastim)

      Terminated
      Has Results
      • Childhood Choroid Plexus Tumor
      • +10 more
      • filgrastim
      • Detroit, Michigan
        Barbara Ann Karmanos Cancer Institute
      Oct 2, 2020

      Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma Trial in Zhengzhou, Shengyang, Hangzhou (HRS-3738)

      Recruiting
      • Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
      • Zhengzhou, Henan, China
      • +2 more
      Jul 27, 2022

      Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

      Recruiting
      • Recurrent Acute Lymphoblastic Leukemia
      • +15 more
      • Anti-CD19/CD20/CD22 CAR T-Cells
      • +2 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Nov 4, 2022

      Cardiovascular Events Among Adults Relapsed or Refractory

      Recruiting
      • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
      • +9 more
      • Electronic Health Record Review
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 5, 2022